

Datasheet: 1351116

Description:	VIVAFIX 547/573 CELL VIABILITY ASSAY
Name:	VIVAFIX™ ASSAY
Format:	547/573
Product Type:	Accessory Reagent
Quantity:	200 TESTS

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/500

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Information

VivaFix cell viability assays are easy-to-use, versatile solutions for assessing the viability of mammalian cells by flow cytometry and microscopy. In most flow cytometry experiments, the exclusion of dead cells within a sample is an important step to prevent erroneous interpretation of the data caused by nonspecific fluorescence signals. When performing cell imaging experiments, cell viability and live:dead ratio are parameters that are frequently evaluated to measure cell health.

The proprietary dyes in the VivaFix Cell Viability Assay can easily assist researchers with distinguishing between live and dead cells by covalently binding to primary amines. In live cells, the VivaFix Dyes bind to the cell surface primary amines. In dead cells, where the plasma membrane is compromised, the dyes are able to permeate the cell and also react with intracellular primary amines. As a result, a greater number of fluorophores is associated with dead cells and at least a 100-fold difference in fluorescence intensity is measured between the live and dead cells thereby allowing an easier discrimination between two populations. VivaFix Dyes are compatible with cell fixation without any significant loss of fluorescence.

Reagents In The Kit Kit includes 4 x 50 assay vials and 250 µl of DMSO, for running 200 assays

Instructions For Use **Important:** Thaw all components prior to use.

Note 1: Any buffer without sodium azide, serum or protein can be used instead of phosphate buffered saline.

Note 2: For multicolor experiments, the cells can be stained with the antibodies of your choice before or after staining with VivaFix Dye. Antibody staining conditions should be optimized for your assay.

1. Prepare a 500x stock solution by adding 50 µl of dimethyl sulfoxide (DMSO) to a VivaFix Dye vial and mix by vortexing.
2. Wash cells once with phosphate buffered saline, then resuspend cells at $2-3 \times 10^6$ cells/ml in phosphate buffered saline. Use 0.5 ml of cell suspension per assay.
3. Add 1 µl of 500x dye stock solution (from step 1) to 0.5 ml cells/assay and mix by vortexing.
4. Incubate the mixture for 30 min at room temperature (RT) or in a 37°C/5% CO₂ incubator. Protect from light.

Note: The optimal dye concentration and incubation time for different cell lines should be assessed empirically.

5. Wash cells twice in phosphate buffered saline.

6. Fix cells as desired. For 3.7% formaldehyde:

-Suspend cells in 900 µl of phosphate buffered saline following step 5

-Add 100 µl of 37% of formaldehyde to the cell suspension

-Incubate for 15 min at room temperature, then wash cells twice with phosphate buffered saline

7. Resuspend cells in the appropriate flow analysis buffer.

8. Sort cells with an [S3e Cell Sorter](#), analyze cells with a flow cytometer, view and capture an image of cells with the [ZOE Fluorescent Cell Imager](#), or view cells with a conventional fluorescence microscope.

References

1. Ramendra, R. *et al.* (2021) Glutathione Metabolism Is a Regulator of the Acute Inflammatory Response of Monocytes to (1→3)-β-D-Glucan. [Front Immunol. 12: 694152.](#)
2. Globig, P. *et al.* (2021) Slow degrading Mg-based materials induce tumor cell dormancy on an osteosarcoma-fibroblast coculture model [Bioactive Materials. 30 Dec \[Epub ahead of print\].](#)
3. Méndez-Solís, O. *et al.* (2021) Kaposi's sarcoma herpesvirus activates the hypoxia response to usurp HIF2α-dependent translation initiation for replication and oncogenesis. [Cell Rep. 37 \(13\): 110144.](#)

4. Manirarora, J.N. *et al.* (2022) Development and Characterization of New Monoclonal Antibodies Against Porcine Interleukin-17A and Interferon-Gamma [Frontiers in Immunology. 13 \[Epub ahead of print\].](#)
5. Ravi, V.M. *et al.* (2022) T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. [Nat Commun. 13 \(1\): 925.](#)
6. Manirarora, J.N. *et al.* (2022) Development and Characterization of New Monoclonal Antibodies Against Porcine Interleukin-17A and Interferon-Gamma. [Front Immunol. 13: 786396.](#)
7. Bouch, S. *et al.* (2022) Therapeutic stem cell-derived alveolar-like macrophages display bactericidal effects and resolve *Pseudomonas aeruginosa*-induced lung injury. [J Cell Mol Med. 26 \(10\): 3046-3059.](#)

Storage	Store at -20°C only
Guarantee	Guaranteed until date of expiry. Please see product label.
Health And Safety Information	Material Safety Datasheet documentation #1351111 available at: 1351111: https://www.bio-rad-antibodies.com/uploads/MSDS/1351111.pdf
Regulatory	For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M393595:220112'

Printed on 18 May 2022